Stock Market & Financial Investment News

News Breaks March 10, 2013 15:19 EDT GILD Gilead's Ranexa reduces angina frequency in study with type 2 diabetes Gilead Sciences announced data from the Phase 4 TERISA (Type 2 Diabetes Evaluation of Ranolazine In Subjects With Chronic Stable Angina) study, which demonstrated that the addition of ranolazine to background antianginal therapy in chronic angina patients with type 2 diabetes significantly reduced the frequency of weekly angina episodes compared to placebo and background antianginal therapy. Results were presented today during a Late-Breaking Clinical Trial session at the American College of Cardiology's 62(nd) Annual Scientific Session (ACC.13) in San Francisco and were published online ahead of print in the Journal of the American College of Cardiology. News For GILD From The Last 14 Days Check below for free stories on GILD the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 07:28 EDT GILD Wells Faro to host a conference Subscribe for More Information June 17, 2013 16:00 EDT GILD Options Update; June 17, 2013 Subscribe for More Information 06:25 EDT GILD Gilead reports interim Phase 2 data for Idelalisib Gilead announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin’s lymphoma that is refractory to rituximab and to alkylating-agent-containing chemotherapy. Previously, this has been a largely unstudied population for which there is significant unmet medical need for effective therapy. In the study, single-agent treatment with idelalisib achieved an overall response rate of 53.6%, with a median duration of response at this interim analysis of 11.9 months. The most common Grade ≥3 adverse event was diarrhea . Grade ≥3 transaminase elevations were reported via central laboratory testing in 13% of patients; Grade ≥3 neutropenia occurred in 26% of patients. Sixteen percent of patients discontinued due to adverse events. June 13, 2013 10:05 EDT GILD On The Fly: Analyst Upgrade Summary Subscribe for More Information 07:33 EDT GILD Gilead upgraded to Buy from Hold at Argus Subscribe for More Information June 10, 2013 07:40 EDT GILD Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information June 7, 2013 17:21 EDT GILD Gilead announces U.S. FDA priority review designation for Sofosbuvir Subscribe for More Information June 6, 2013 09:07 EDT GILD Gilead Sofosbuvir likely to be granted priority review, says RBC Capital Subscribe for More Information 08:27 EDT GILD Bernstein's biotech analysts hold an analyst/industry conference call Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.